Cassie Liu

Dr. Cassie Liu

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CLCassie Liu
Cassie Liu
CBCarter Barger
Carter Barger
Adam R KarpfAdam R Karpf
Adam R Karpf
Forkhead box M1 (FOXM1) is a member of the conserved forkhead box (FOX) transcription factor family. Over the last two decades, FOXM1 has emerged as a multifunctional oncoprotein and a robust biomarker of poor prognosis in many human malignancies. In this review article, we address the current knowledge regarding the mechanisms of regulation and oncogenic functions of FOXM1, particularly in the context of ovarian cancer. FOXM1 and its associated oncogenic transcriptional signature are enriched in >85% of ovarian cancer cases and FOXM1 expression and activity can be enhanced by a plethora of genomic, transcriptional, post-transcriptional, and post-translational mechanisms. As a master transcriptional regulator, FOXM1 promotes critical oncogenic phenotypes in ovarian cancer, including: (1) cell proliferation, (2) invasion and metastasis, (3) chemotherapy resistance, (4) cancer stem cell (CSC) properties, (5) genomic instability, and (6) altered cellular metabolism. We additionally discuss the evidence for FOXM1 as a cancer biomarker, describe the rationale for FOXM1 as a cancer therapeutic target, and provide an overview of therapeutic strategies used to target FOXM1 for cancer treatment.

7 November 2011 in Biochemistry
Verified
Journal Article
Open access
DCDaniel J. Czyzyk
Daniel J. Czyzyk
CLCassie Liu
Cassie Liu
ETErika Taylor
Erika Taylor
Heptosyltransferase I (HepI) is responsible for the transfer of l-glycero-d-manno-heptose to a 3-deoxy-α-d-oct-2-ulopyranosonic acid (Kdo) of the growing core region of lipopolysaccharide (LPS). The catalytic efficiency of HepI with the fully deacylated analogue of Escherichia coli HepI LipidA is 12-fold greater than with the fully acylated substrate, with a kcat/Km of 2.7 × 106 M–1 s–1, compared to a value of 2.2 × 105 M–1 s–1 for the Kdo2-LipidA substrate. Not only is this is the first demonstration that an LPS biosynthetic enzyme is catalytically enhanced by the absence of lipids, this result has significant implications for downstream enzymes that are now thought to utilize deacylated substrates.

16 March 2023 in Journal of Central Nervous System Disease
Verified
Journal Article
Open access
CLCassie Liu
Cassie Liu
JCJoseph Carmicheal
Joseph Carmicheal
MBMichael J. Baine
Michael J. Baine
CZChi Zhang
Chi Zhang
Pineal parenchymal tumor of intermediate differentiation (PPTID) is a rare, primary tumor of the pineal gland. Due to its rarity, there is no consensus on optimal therapeutic strategies or standard characterization of the tumor’s behavior. Here, we report 2 new cases of PPTID and an extensive review of the literature involving the use and extent of radiation therapy. Patient 1 is a 54-year-old male who presented with PPTID and drop metastases in the spinal cord, received cranial spinal irradiation (CSI), and experienced recurrence 3.5 years after treatment. Stereotactic body radiation therapy (SBRT) helped the patient into remission for 9 months. Patient 2 is a 32-year-old male with a local PPTID at presentation who went on to receive surgical resection followed by focused adjuvant radiation therapy to the pineal tumor bed. He then presented 6 years after treatment with extensive disseminated recurrence and died due to leptomeningeal disease (LMD) about 4 years after recurrence. The available literature on PPTID is limited and reported cases of LMD with ongoing follow-up in PPTID are scarce. Our report adds to the current known PPTID cases, contributing to the information available regarding prognosis and treatment response. Although an optimal therapeutic strategy for PPTID still cannot be determined, data from the literature suggest that utilizing radiation therapy in patients with low-risk disease and gross total resections as well as the use of upfront CSI have the potential to improve patient progression and survival outcomes.

24 March 2025 in Cancer Medicine
Verified
Journal Article
Open access
CLCassie Liu
Cassie Liu
KSKaeli K. Samson
Kaeli K. Samson
OSOleg Shats
Oleg Shats
RBRaymond Bergan
Raymond Bergan
Introduction: Studies focused on rural–urban disparities in patients with prostate cancer have demonstrated minimal differences in incidence and overall survival (OS). However, available data are limited, especially in understudied geographic locations. In this study, we investigated additional measures of potential cancer disparity and focused on examining rural–urban prostate cancer disparity in Nebraska residents.Methods: Patients diagnosed with prostate cancer from 1991 to 2023 living in Nebraska were identified in the integrated Cancer Repository for Cancer Research (iCaRe2) and categorized as rural and urban by rural–urban commuting area (RUCA) codes.Results: Results are presented as mean ± standard deviation. The iCaRe2 patient registry contained data on 765 men with prostate cancer living in Nebraska, 621 (81.2%) of whom were urban residents and 144 (18.8%) of whom were rural residents. Rural residents were diagnosed with prostate cancer 3.1 years younger than urban residents (rural: 65.6 ± 8.21 years, urban: 68.7 ± 9.08 years, p < 0.001). Rural residents died of prostate cancer 4.2 years younger than urban residents (rural: 72.9 ± 9.75 years, urban: 77.1 ± 8.85 years, p < 0.001). Analyses of Gleason score and AJCC stage did not reveal statistically significant differences between rural and urban residents. OS was similar between rural and urban men in Nebraska with prostate cancer, congruent with currently published literature.Conclusions: Our analysis demonstrates that rural patients in Nebraska are diagnosed and die with prostate cancer at younger ages compared to urban patients. Our findings offer strategies to better define and delineate rural–urban cancer disparity and support future, more robust investigations to consider novel approaches to determining disparities in cancer disease course.

6 December 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
CLCassie Liu
Cassie Liu
MBMichael J. Baine
Michael J. Baine
KFKurt Fisher
Kurt Fisher
JAJames O. Armitage
James O. Armitage
CECharles A. Enke
Charles A. Enke